Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Infections × monalizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Infections 1 COVID-19 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

telavancin 1 monalizumab 1 fludarabine phosphate 1 fish oil triglycerides 1 avdoralimab 1 Whole-Body Irradiation 1 Voriconazole 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Therapeutics 1 Tacrolimus 1 Standard of Care 1 Sirolimus 1 Peripheral Blood Stem Cell Transplantation 1 Observation 1 Methotrexate 1 Melphalan 1 Interferon-gamma 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1 Hematopoietic Stem Cell Transplantation 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Cyclophosphamide 1 Clarithromycin 1 Caspofungin 1 Bevacizumab 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04333914 2022-09-30

IMMUNONCOVID

Centre Leon Berard

Phase 2 Completed

COVID-19, Infections, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡